FdaApplication
NDA 208223
Identifiers
- fda_app_no: NDA208223
Properties
| Property | Value |
|---|---|
| applicant_name | TONIX MEDICINES INC |
| application_type | NDA |
| approval_date | 2016-01-28 |
Revenue by product
ZEMBRACE SYMTOUCH
| Period | Revenue |
|---|---|
| Q2 2026 | $2.0M |
| Q1 2026 | $2.9M |
| Q4 2025 | $3.1M |
| Q3 2025 | $2.6M |
| Q2 2025 | $1.6M |
| Q1 2025 | $2.0M |
| Q4 2024 | $2.5M |
| Q3 2024 | $2.5M |
| Q2 2024 | $1.7M |
| Q1 2024 | $1.8M |
| Q4 2023 | $3.0M |
| Q3 2023 | $3.3M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ZEMBRACE SYMTOUCH (AUTOINJECTOR) | SUMATRIPTAN SUCCINATE | EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) | SOLUTION;SUBCUTANEOUS |
1 product